BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers & Acquisitions (M&A), Strategy and Global Business Development. Before Aptalis, Theresa was with Novartis for 9+ years and held positions of increasing responsibility including Head, Global BD&L for General Medicines, Executive Director and Head, Global BD&L for Respiratory and Dermatology Business Units and Head US Business Development & Licensing, Life cycle management and generic brand strategies.
Theresa has a Masters Degree in Biochemistry from University of Maryland and is a Juris Doctor (J.D) from the Widener University School of Law, Wilmington, Delaware. She started her career as a research scientist at Dupont and has practiced Corporate Law at Pennie & Edmonds (Jones Day). Having worked with Aptalis and Novartis, Theresa has over 27 years of experience in the Pharmaceutical and Biotech sector with significant experience in managing strategy, corporate development, M&A and licensing.
Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, "I am very pleased to welcome Theresa to the Lupin family. I am sure her rich experience in the areas of M&A and Specialty Strategy within the Pharmaceutical and Biotech industry sector will help Lupin's growth plans."
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit http://www.lupinworld.com for more information.
For further information or queries please contact -
Head – Corporate Communications
Ph: +91 98 20 338 555
Email: [email protected]
SOURCE Lupin Limited